Group 1 - Several pharmaceutical companies have acknowledged rumors regarding potential restrictions on innovative drugs from China in the U.S. market, but they believe these rumors do not currently affect the expectations for Chinese innovative drugs going abroad [1] - Market analysts expect leading biotech companies, such as BeiGene and Innovent Biologics, to reach a profitability inflection point by 2025, with the potential for sustained high growth thereafter [1] - With improvements in industrialization capabilities and product line expansion, it is anticipated that more biotech companies will enter a profitability cycle in the future [1] Group 2 - Following a significant drop yesterday, Hong Kong's innovative drug concept stocks rebounded across the board today, with CStone Pharmaceuticals rising over 14%, Hutchison China MediTech increasing over 6%, Zai Lab and Lepu Biopharma both up over 5%, and Akeso rising over 4% [2]
创新药板块全线反弹
Di Yi Cai Jing·2025-09-12 03:31